Hatteras Venture Partners overview
Stories about Hatteras Venture Partners
Hatteras Venture Partners collects over $137.2m for sixth fund
Hatteras Venture Partners has raised over $137.2 million for its sixth fund, according to an SEC filing.
410 Medical nabs $8 mln Series A
Durham, North Carolina-based 410 Medical Inc, a medical device company, has raised $8 million in Series A financing. Hatteras Venture Partners led the round with participation from other investors that included OSF Healthcare.
Hatteras amasses $94 mln for sixth fund
Hatteras Venture Partners has raised $94 million for its sixth fund. The target is $200 million. The Durham, North Carolina-based venture firm makes seed and early-stage investments in health care.
VC-backed StrideBio recruits Shah as CEO
Durham, North Carolina-based StrideBio Inc, a gene therapy company, has named Dr. Sapan Shah as CEO and a member of the company's board. Shah is a former chief executive at ARMGO Pharma and Ezose Sciences. StrideBio's backers include Hatteras Venture Partners, Takeda Ventures Inc, UCB Ventures and Alexandria Venture Investments LLC.
StrideBio grabs $15.7 mln Series A
Durham, North Carolina-based StrideBio Inc, a developer of novel AAV vectors for in vivo gene therapies, has raised $15.7 million in Series A funding. Hatteras Venture Partners led the round with participation from other investors that included Takeda Ventures Inc, UCB Ventures and Alexandria Venture Investments LLC. In addition to the funding, Dr. Jayson Punwani, a partner at Takeda Ventures Inc. and Dr. Erica Whittaker, vice president and head of UCB Ventures, have joined StrideBio's board of directors.
Biotech company Ribometrix snags $7.5 mln seed
Ribometrix Inc, a biotech company focused on developing small molecule modulators of RNA to treat disease, has raised $7.5 million in seed funding. SV Health Investors and Hatteras Venture Partners led the round with participation from AbbVie Ventures, the Dementia Discovery Fund, MP Healthcare Venture Management and Alexandria Venture Investments.
Biotech company ORIG3N nabs $20 mln
Boston-based ORIG3N, a biotechnology company that is developing treatments for rare and genetically inherited diseases, has raised $20 million in funding. Hatteras Venture Partners led the round with participation from Spectrum Health Ventures, LabCorp, Syno Capital, KTB-KORUS Fund, MGC Venture Partners, DEFTA Partners and 180 Degree Capital. In conjunction with the funding, Byron Smith, a principal at Mountain Group Partners, has been added to ORIG3N's board of directors.
Hatteras Venture Partners and Malin back Artizan
Durham, North Carolina-based Artizan Biosciences Inc, a new biotech company, has secured an undisclosed amount of funding. The investors were Malin, which acquired a 32 percent stake in Artizan and Hatteras Venture Partners.
Hatteras Venture Partners contact information
Offices
280 S. Mangum St., Suite 350, Durham, 27701, United StatesContacts
| Name | Job title | Location | |
|---|---|---|---|
Key Contact Mr. Parker Johnson | Job titleHead of Investor Relations and Client Development | LocationDurham, United States | Email  ----------- |
| Mr. Alston Gardner | Job titleManaging Partner | LocationDurham, United States | Email ------- |
| Mr. Ned Sharpless | Job titleManaging Director | LocationDurham, United States | Email ------- |
| Mr. John Crumpler | Job titleGeneral Partner | LocationDurham, United States | Email ------- |
Hatteras Venture Partners fund commitments
Known fund commitments: 2
| Fund | Manager | Commitment date | Commitment size |
|---|---|---|---|
Manager ----- | Commitment date- | Commitment size- | |
Manager -------- | Commitment date- | Commitment size ------ | |
Hatteras Venture Partners funds managed
Funds in market: 1
| Fund | Fund size | Open date | Strategy |
|---|---|---|---|
Fund size ------ | Open date- | Strategy ----- | |
Closed funds: 10
| Fund | Fund size | Close date | Strategy |
|---|---|---|---|
Fund size ---------- | Close dateMar 2024 | Strategy ---------- | |
Fund size ----------- | Close dateAug 2023 | Strategy ----- | |
Fund size --------- | Close dateOct 2020 | Strategy --------- | |
Stories that mention Hatteras Venture Partners
Hatteras collects over $200m across two funds
In addition to the closing of the funds, Hatteras has promoted Dr. Ben Scruggs and Lauren Flickinger to partner.
Code Biotherapeutics pulls in $75m Series A
Code Biotherapeutics, a biotech firm, has raised $75 million in Series A financing.
VC-backed CVRx rolls out IPO
Minneapolis-based CVRx Inc, a medical device firm, has raised about $126 million for its IPO after pricing its 7 million shares at $18 per share.
VC-backed Target RWE buys NoviSci
Target RWE has acquired Durham, North Carolina-based NoviSci Inc, a software analytics and services company.
VC-backed Qpex Biopharma names chief business officer
Qpex Biopharma Inc, a developer of anti-infective therapies, has appointed Paul Westberg as chief business officer.
Graybug Vision procures $80 mln Series C
Silicon Valley-based Graybug Vision Inc, a clinical stage pharmaceutical company, has secured $80 million in Series C financing. CBC Group led the round with participation from other investors that included Deerfield Management, OrbiMed Advisors and Hatteras Venture Partners.
Trefoil reels in $28 mln
San Diego-based Trefoil Therapeutics, a biotech firm, has secured $28 million in financing. Bios Partners led the round with participation from other investors that included Access Biotechnology, Hatteras Venture Partners, Aju IB Investment, Correlation Ventures, ExSight Ventures and InFocus Capital Partners.